• Explore /
  • Poster
  • / Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E)

Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E)

Abstract Poster

Authors

Ethan Basch

Ethan M. Basch

The University of North Carolina at Chapel Hill, Chapel Hill, NC

Ethan M. Basch , Mark C. Scholz , Johann Sebastian De Bono , Nicholas J. Vogelzang , Paul L. De Souza , Gavin M. Marx , Ulka N. Vaishampayan , Saby George , James K. Schwarz , Emmanuel S. Antonarakis , Joe M. O'Sullivan , Arash Rezazadeh Kalebasty , Kim N. Chi , Robert Dreicer , Thomas E. Hutson , Milan Mangeshkar , Jaymes S. Holland , Aaron Weitzman , Howard I. Scher

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT01522443

Citation

J Clin Oncol 33, 2015 (suppl 7; abstr 141)

DOI

10.1200/jco.2015.33.7_suppl.141

Abstract #

141

Poster Bd #

A10

Abstract Disclosures

Similar Posters

First Author: Niven Mehra

First Author: Gregory Russell Pond

First Author: Thomas W. Flaig

First Author: Joaquin Mateo